TL;DR
Biotech cyber insurance sizing follows stage: pre-IND biotech typically buys $1M-$3M, Phase 1-2 buys $3M-$5M, IPO-readiness operators buy $5M-$15M, commercial-stage biotech buys $15M-$50M plus. The cyber program needs to address IND data protection, clinical PHI handling under HIPAA, state privacy law overlays, drug master file (DMF) trade secret exposure, and the IPO-readiness underwriter audit standard which is materially stricter than pre-IPO. Premium for a Texas pre-IPO biotech with a $5M cyber tower typically runs $20K-$60K annually.
Biotech cyber
Biotech cyber insurance - clinical-stage through IPO-readiness.
Cyber coverage for a biotech operator is fundamentally different from cyber coverage for a general technology company. The biotech operator holds investigational new drug application (IND) data, clinical PHI, drug master files (DMF), proprietary cell lines and chemistry, plus sponsor partnerships and licensing agreement IP. Each of these is an insurable cyber exposure with specific coverage demands, and IPO-readiness diligence stress-tests the cyber program in ways that pre-IPO biotech operators often underestimate.
Tower sizing by stage
Cyber program scales materially at each funding round.
Pre-IND biotech: $1M to $3M cyber tower. Below $1M leaves DMF and platform-IP exposure unfunded; above $3M is hard to justify at pre-revenue.
Phase 1 to Phase 2 clinical: $3M to $5M tower. The active CTA portfolio and patient PHI handling drive the upper end. Multi-site international Phase 2 typically pushes to $5M.
IPO-readiness and post-IPO: $5M to $15M tower. The IPO underwriter cyber diligence is materially stricter than pre-IPO; operators that pass that diligence on a $3M tower are unusual.
Commercial-stage biotech: $15M to $50M plus tower. Commercial product distribution, patient assistance programs, and direct-to-consumer marketing add cyber exposures that pre-commercial operators do not face.
Required endorsements
Standard cyber forms do not address biotech-specific exposures.
Drug master file (DMF) trade secret coverage: Theft or unauthorized disclosure of DMF content is a material biotech exposure that standard cyber forms typically do not address. Specific trade secret extension wording is required.
IND data protection: Coverage for unauthorized disclosure of unpublished trial data. Standard cyber forms cover PHI but not necessarily the broader IND data category. Verify wording.
HIPAA Business Associate coverage: For any operator handling PHI from clinical sites or CROs, explicit BA coverage is required. Civil monetary penalties under HITECH are insurable but require specific endorsement.
Regulatory defense for state privacy laws: Multi-state clinical trial activity requires coverage for the strictest applicable state privacy regime - WA MHMDA, Connecticut, Maryland MOPDPA, California CMIA/CCPA, Texas TDPSA.
IPO-readiness underwriter representation coverage: Securities-class-action exposure tied to cyber events is part of the IPO underwriter representation. Cyber coverage should coordinate with D&O architecture rather than leave gaps.
Sponsor partnership PHI / DMF flows: Many sponsor partnerships involve PHI or DMF data flows from sponsor to biotech. The cyber policy should address breach response when the breach occurs at the sponsor but affects the biotech's data holdings.
Premium ranges
What Texas biotech pays for the program above.
Pre-IND biotech with $1M-$3M tower: $8K to $25K annually.
Phase 1-2 clinical with $3M-$5M tower: $15K to $40K annually.
IPO-readiness with $5M-$15M tower: $30K to $80K annually.
Commercial-stage biotech with $15M-$50M tower: $75K to $250K annually.
Premium adjusts up materially for prior loss history, lack of MFA, lack of formal incident response, or expanding international operations. Premium credits apply for SOC 2, ISO 27001, 24/7 SOC monitoring, and zero-trust architecture.
Biotech cyber review